Filing Analysis
Milestone Pharmaceuticals Inc. filed an 8-K to announce its financial results for the second quarter ended June 30, 2026. The filing serves as a formal notice that a press release containing business highlights and quarterly earnings has been issued.
📋 Key Facts
- Reporting period: Second Quarter ended June 30, 2026.
- Filing date: August 12, 2026.
- The company issued a press release (Exhibit 99.1) detailing financial results and business highlights.
Milestone Pharmaceuticals Inc. reported the results of its 2026 Annual Meeting of Shareholders held on June 10, 2026. Key outcomes include the election of the Board of Directors, ratification of PwC as the auditor, and the approval of an amendment to the 2019 Equity Incentive Plan.
🚩 Red Flags
- Significant potential dilution: The increase of 6.8 million shares for the equity incentive plan may dilute existing shareholders, depending on the current total shares outstanding.
📋 Key Facts
- Shareholders approved an amendment to the 2019 Equity Incentive Plan (2019 EIP) increasing authorized ordinary shares for issuance by 6,800,000 shares.
- PricewaterhouseCoopers LLP was ratified as the company's auditor until the 2027 Annual Meeting.
- Eight directors were elected to the Board: Joseph Oliveto, Stuart M. Duty, Seth H.Z. Fischer, Lisa M. Giles, Joseph C. Papa, Andrew R. Saik, Michael Tomsicek, and Robert J. Wills.
- A non-binding advisory vote on executive compensation was approved.
Milestone Pharmaceuticals Inc. announced its financial results for the first quarter ended March 31, 2026. The filing serves to furnish the earnings press release and provide business highlights for the period.
📋 Key Facts
- The report was filed on May 13, 2026, covering the fiscal quarter ended March 31, 2026.
- The disclosure was made under Item 2.02 (Results of Operations and Financial Condition).
- The company furnished a press release as Exhibit 99.1.
- Amit Hasija, Chief Financial Officer, signed the report.
Milestone Pharmaceuticals Inc. announced its fourth quarter and full-year 2025 financial results and provided a commercial update on its lead product, CARDAMYST™ (etripamil) Nasal Spray.
📋 Key Facts
- Financial results reported for the fiscal year and quarter ended December 31, 2025.
- Provided a commercial launch update for CARDAMYST™ (etripamil) Nasal Spray for the treatment of Paroxysmal Supraventricular Tachycardia (PSVT).
- The filing was made under Item 2.02 (Results of Operations and Financial Condition).
- Amit Hasija, Chief Financial Officer, signed the report on March 20, 2026.
Milestone Pharmaceuticals Inc. issued a press release announcing the availability of CARDAMYST (etripamil) nasal spray for managing paroxysmal supraventricular tachycardia (PSVT) in the United States.
📋 Key Facts
- Product Name: CARDAMYST (etripamil) nasal spray
- Indication: Management of paroxysmal supraventricular tachycardia (PSVT)
- Market Availability: Announced availability in the United States on January 26, 2026.
- Filing Type: Item 8.01 (Other Events)
Milestone Pharmaceuticals Inc. has closed the sale of its royalty interest in etripamil to RTW Royalty I DAC, receiving a $75.0 million lump sum payment.
🚩 Red Flags
- Loss of future recurring revenue stream (royalties) in exchange for immediate cash infusion.
📋 Key Facts
- Closed the sale of royalty interest on January 12, 2026.
- Received a total purchase price of $75.0 million from funds managed by RTW Investments, LP.
- The transaction involves tiered quarterly royalty payments on annual net product sales of etripamil in the United States.
- The original agreement was entered into on March 27, 2023.
Milestone Pharmaceuticals announced that the European Medicines Agency (EMA) has accepted its Marketing Authorization Application for etripamil nasal spray. A decision regarding approval is anticipated by Q1 2027.
📋 Key Facts
- The EMA has accepted the Marketing Authorization Application for etripamil nasal spray.
- A regulatory decision on the application is expected by the first quarter of 2027.
- The announcement was made via a press release dated January 6, 2026.
Milestone Pharmaceuticals announced the FDA approval of CARDAMYST (etripamil) nasal spray for managing paroxysmal supraventricular tachycardia (PSVT). The company also released a corporate presentation to support investor communications.
📋 Key Facts
- FDA approved New Drug Application for CARDAMYST (etripamil) nasal spray on December 12, 2025.
- Indication: Management of paroxysmal supraventricular tachycardia (PSVT).
- Company released a corporate presentation dated December 15, 2025, as Exhibit 99.1.
Milestone Pharmaceuticals Inc. filed an 8-K to announce its third quarter financial results for the period ended September 30, 2025, alongside a regulatory and corporate update.
📋 Key Facts
- Report date: November 12, 2025
- Reporting period: Third Quarter ended September 30, 2025
- The filing includes an announcement of financial results and a regulatory/corporate update via Exhibit 99.1.
- Company is listed on the Nasdaq Stock Market under ticker MIST.
Milestone Pharmaceuticals Inc. filed an 8-K to announce its second quarter 2025 financial results and provide a regulatory/corporate update via press release.
📋 Key Facts
- Report date: August 12, 2025
- Reporting period: Second Quarter ended June 30, 2025
- The filing includes an announcement of financial results and a regulatory/corporate update via Exhibit 99.1.
Milestone Pharmaceuticals Inc. entered into an underwriting agreement on July 11, 2025, to conduct a public offering of common shares and various warrants (Series A, Series B, and Pre-Funded Warrants). The offering is expected to raise approximately $48.7 million in net proceeds.
🚩 Red Flags
- Significant dilution: The issuance of up to 96.5 million total securities (shares + warrants) represents a massive expansion of the share count.
- Warrant overhang: Series B warrants have a 5-year term and include mandatory exercise provisions if the stock price stays above $3.50 for 10 consecutive days, which can create volatility.
- Pre-funded warrants with $0.001 exercise price: These are essentially immediate equity issuances that bypass certain ownership limitations but cause significant dilution.
📋 Key Facts
- Public offering includes 31,500,000 common shares at $1.50 per share.
- Accompanying Series A Common Warrants: 31,500,000 warrants to purchase shares at $1.50 (1-year expiry).
- Accompanying Series B Common Warrants: 31,500,000 warrants to purchase shares at $1.875 (5-year expiry).
- Pre-funded warrants for 3,502,335 common shares at a price of $1.499 per warrant.
- Net proceeds expected to be approximately $48.7 million after expenses.
- Underwriters include TD Securities (USA) LLC, Piper Sandler & Co., and Wells Fargo Securities, LLC.
- The offering is being conducted via an S-3 registration statement declared effective on November 22, 2024.
Milestone Pharmaceuticals entered into an amendment to its Royalty Purchase Agreement with RTW Royalty I DAC, extending the Marketing Approval Deadline to December 31, 2025. Additionally, the FDA has accepted a response regarding the CARDAMYST NDA, setting a new PDUFA target date of December 13, 2025.
🚩 Red Flags
- The extension of the Marketing Approval Deadline suggests potential delays in achieving key milestones required by royalty partners.
- Previous Complete Response Letter (CRL) indicates prior regulatory hurdles for CARDAMYST.
📋 Key Facts
- Amendment to Royalty Purchase Agreement with RTW Royalty I DAC extends Marketing Approval Deadline from Sept 30, 2025, to Dec 31, 2025.
- FDA accepted the Company's response to issues raised in a previous Complete Response Letter (CRL) for CARDAMYST (etripamil).
- New PDUFA target action date set for December 13, 2025.
Milestone Pharmaceuticals announced the submission of a response to an FDA Complete Response Letter (CRL) regarding its New Drug Application for CARDAMYST nasal spray. The company is attempting to address previous regulatory concerns to advance the drug's approval process.
🚩 Red Flags
- The existence of a prior Complete Response Letter (CRL) indicates that the FDA previously identified deficiencies in the application that must be addressed to achieve approval.
📋 Key Facts
- Company submitted a response to the FDA's Complete Response Letter on June 16, 2025.
- The submission pertains to the New Drug Application (NDA) for CARDAMYST (etripamil) nasal spray.
- CARDAMYST is indicated for the management of paroxysmal supraventricular tachycardia.
Milestone Pharmaceuticals Inc. reported the results of its 2025 Annual Meeting of Shareholders held on June 10, 2025. The meeting included the election of directors and several shareholder proposals regarding equity incentive plans and auditor ratification.
🚩 Red Flags
- Significant 'Against' vote on Proposal 3 (Equity Incentive Plan amendment) with 4,738,058 votes against compared to 8,036,707 for.
📋 Key Facts
- Shareholders elected eight nominees to the Board of Directors to serve until the 2026 Annual Meeting.
- PricewaterhouseCoopers LLP was ratified as the Company's auditor through the close of the 2026 Annual Meeting.
- Shareholders approved an amendment to the 2019 Equity Incentive Plan (EIP) to remove the 'evergreen provision'.
- The 2019 EIP was amended to increase the number of ordinary shares authorized for issuance by 4,000,000 shares.
- Shareholders approved a non-binding advisory vote on executive compensation frequency, opting for a 1-year cycle (12,291,479 votes in favor).
Milestone Pharmaceuticals Inc. filed an 8-K to announce its financial results for the first quarter ended March 31, 2025, and provided a regulatory and corporate update.
📋 Key Facts
- Reporting period: First Quarter ended March 31, 2025
- Filing date: May 14, 2025
- The filing includes an announcement of financial results and a regulatory/corporate update via Exhibit 99.1.
Milestone Pharmaceuticals announced that the FDA issued a Complete Response Letter (CRL) regarding its New Drug Application for CARDAMYST (etripamil) nasal spray. This represents a significant regulatory setback for the company's lead product candidate.
🚩 Red Flags
- Regulatory rejection (CRL) of a primary drug candidate significantly impacts future revenue projections and clinical timelines.
- Potential for increased cash burn if additional clinical trials or studies are required by the FDA to address CRL concerns.
📋 Key Facts
- FDA issued a Complete Response Letter (CRL) for CARDAMYST (etripamil) nasal spray on March 28, 2025.
- The drug is intended for the management of paroxysmal supraventricular tachycardia.
- The filing includes an attached press release as Exhibit 99.1.
Milestone Pharmaceuticals Inc. has announced the dates for its 2025 Annual Meeting of Shareholders and the associated record date. The filing serves to notify shareholders of the meeting schedule and provides deadlines for submitting shareholder proposals or director nominations.
📋 Key Facts
- 2025 Annual Meeting Date: June 10, 2025
- Record Date for voting eligibility: April 15, 2025
- Deadline for Rule 14a-8 shareholder proposals: March 29, 2025
- Deadline for Québec Business Corporations Act/By-law proposals: April 15, 2025
- Deadline for universal proxy rule director nominations (Rule 14a-19): April 11, 2025
Milestone Pharmaceuticals Inc. entered into an Amended and Restated Open Market Sale Agreement with Jefferies LLC to increase the aggregate offering price of common shares from $50 million to $77.8 million via an 'at-the-market' (ATM) offering.
🚩 Red Flags
- Increased ATM offering capacity suggests a need for additional liquidity/cash runway.
- Potential dilution for existing shareholders through the issuance of new common shares.
📋 Key Facts
- Amended and Restated Open Market Sale Agreement signed on March 18, 2025.
- Aggregate offering price increased from $50,000,000 to $77,800,000.
- Includes approximately $2.8 million in sales previously made under the original July 29, 2020 agreement.
- Agent (Jefferies LLC) will sell shares via 'at-the-market' methods on Nasdaq Global Select Market.
- Commission rate is 3.0% of aggregate gross sales proceeds.
- The company is not obligated to make any sales under the agreement.
Milestone Pharmaceuticals Inc. filed an 8-K to announce its financial results for the fourth quarter and fiscal year ended December 31, 2024. The filing includes a press release providing both financial performance data and corporate/regulatory updates.
📋 Key Facts
- Reporting period: Fourth quarter and fiscal year ended December 31, 2024.
- Filing date: March 13, 2025.
- The filing includes a press release (Exhibit 99.1) containing financial results and regulatory updates.
Milestone Pharmaceuticals Inc. filed an 8-K to provide a corporate presentation dated February 25, 2025, intended for use in investor meetings and conferences.
📋 Key Facts
- The company provided a corporate presentation as Exhibit 99.1.
- The filing is made pursuant to Item 7.01 (Regulation FD Disclosure).
- The information furnished under Item 7.01 is not deemed 'filed' for purposes of Section 18 of the Exchange Act.
Milestone Pharmaceuticals Inc. filed an 8-K to announce its third quarter financial results for the period ended September 30, 2024, alongside a clinical and corporate update.
📋 Key Facts
- Reporting date: November 12, 2024
- Period covered: Third Quarter ended September 30, 2024
- The filing includes financial results, clinical updates, and corporate updates via Exhibit 99.1.
Milestone Pharmaceuticals announced the election of Joseph C. Papa to its Board of Directors and Compensation Committee, effective September 3, 2024. The filing also reports results from the company's 2024 Annual Meeting of Shareholders regarding director elections and auditor appointment.
📋 Key Facts
- Joseph C. Papa elected to the Board and Compensation Committee effective Sept 3, 2024.
- Mr. Papa brings extensive leadership experience (former CEO of Bausch + Lomb, Chairman/CEO of Bausch Health and Perrigo).
- Compensation for Mr. Papa includes $42,500 annual cash for board service, $7,500 for compensation committee service, and an option to purchase up to 80,000 common shares.
- Shareholders approved the appointment of PricewaterhouseCoopers LLP (PwC) as auditor through the 2025 Annual Meeting.
- The company held its 2024 Annual Meeting virtually on August 28, 2024.
Milestone Pharmaceuticals Inc. filed an 8-K to announce its second quarter 2024 financial results and provided a clinical and corporate update via press release.
📋 Key Facts
- Reporting period: Second Quarter ended June 30, 2024.
- Filing date: August 8, 2024.
- The filing includes an announcement of financial results, clinical updates, and corporate updates via Exhibit 99.1.
Milestone Pharmaceuticals entered into a Cooperation Agreement with Alta Fundamental Advisers LLC, resolving a potential proxy contest. The agreement involves expanding the Board of Directors to include two new directors nominated by Alta and provides for further board expansion if certain conditions are met.
🚩 Red Flags
- Resolution of a proxy contest indicates significant shareholder activism/disagreement regarding company governance or strategy.
- Board turnover: Two members of the Compensation Committee are departing following the settlement.
- Potential for further board expansion and instability if Alta maintains a Net Long Position above 4.0%.
📋 Key Facts
- Entered into a Cooperation Agreement with Alta Fundamental Advisers LLC on July 14, 2024.
- Board size increased from seven to nine directors to accommodate two new appointees: Stuart M. Duty and Andrew R. Saik.
- Alta withdrew its Rule 14a-19 notice of intention to nominate five directors for the 2024 Annual Meeting.
- The Company will include the new directors on its slate for both the 2024 and 2025 Annual Meetings.
- A third 'Company Identified New Director' will be appointed by September 6, 2024, if mutually agreed upon with Alta.
- Alta has agreed to vote in accordance with Board recommendations on most proposals, subject to specific ISS/Glass Lewis exceptions and extraordinary transactions.
- Two current directors (Debra K. Liebert and Richard Pasternak, MD) will not stand for reelection at the 2024 Annual Meeting.
Milestone Pharmaceuticals announced that the FDA has accepted its resubmitted New Drug Application (NDA) for CARDAMYST (etripamil) nasal spray. The PDUFA target date is set for approximately 10 months from May 26, 2024.
📋 Key Facts
- FDA accepted the resubmitted NDA for CARDAMYST (etripamil) nasal spray on May 26, 2024.
- CARDAMYST is intended for the management of paroxysmal supraventricular tachycardia.
- The Prescription Drug User Fee Act (PDUFA) target date is approximately 10 months from the acceptance date.
Milestone Pharmaceuticals Inc. filed an 8-K to announce its financial results and clinical/corporate updates for the first quarter ended March 31, 2024.
📋 Key Facts
- Report date: May 13, 2024
- Reporting period: First Quarter ended March 31, 2024
- The filing includes a press release (Exhibit 99.1) containing financial results and clinical/corporate updates.
- Company is classified as an emerging growth company.
Milestone Pharmaceuticals Inc. issued a press release regarding new clinical data for etripamil, demonstrating its real-world application in converting paroxysmal supraventricular tachycardia.
📋 Key Facts
- Date of report: April 8, 2024
- Subject matter: New clinical data for etripamil
- Clinical indication: Conversion of paroxysmal supraventricular tachycardia (PSVT)
- Context: Real-world application demonstration
Milestone Pharmaceuticals Inc. announced the resubmission of its New Drug Application (NDA) to the FDA for etripamil nasal spray, intended for the treatment of paroxysmal supraventricular tachycardia.
📋 Key Facts
- Date of event: March 28, 2024
- Action: Resubmission of New Drug Application (NDA) to the U.S. FDA
- Product: Self-administered etripamil nasal spray
- Indication: Treatment of paroxysmal supraventricular tachycardia
Milestone Pharmaceuticals Inc. issued an 8-K to announce its financial results for the fourth quarter and fiscal year ended December 31, 2023, alongside a regulatory and corporate update.
📋 Key Facts
- Report covers Q4 and full fiscal year ended December 31, 2023.
- Filing date is March 21, 2024.
- The company included a press release (Exhibit 99.1) containing regulatory and corporate updates.
Milestone Pharmaceuticals Inc. entered into an underwriting agreement to conduct a public offering of common shares and pre-funded warrants. The offering aims to raise approximately $32.4 million in net proceeds.
🚩 Red Flags
- Significant dilution: The issuance of over 16 million new shares represents substantial potential dilution for existing shareholders.
- Low share price: Offering price of $1.50 per share is characteristic of micro-cap companies facing capital constraints.
- Pre-funded warrants: Use of pre-funded warrants often indicates a need for immediate capital where investors want to avoid certain ownership thresholds.
📋 Key Facts
- Underwriting agreement signed with Piper Sandler & Co. on February 28, 2024.
- Offering includes 16,666,667 common shares at $1.50 per share.
- Offering includes 3,333,333 pre-funded warrants at $1.499 per warrant (exercise price of $0.001).
- Underwriters fully exercised their option to purchase an additional 3,000,000 common shares on February 29, 2024.
- Expected net proceeds are approximately $32.4 million after commissions and expenses.
- Pre-funded warrants include a 9.99% beneficial ownership limitation.
Milestone Pharmaceuticals announced the results of a Type A meeting with the FDA regarding its New Drug Application (NDA) for etripamil nasal spray. The company intends to resubmit the application following feedback received during this meeting.
🚩 Red Flags
- Regulatory delay: The need to resubmit an NDA implies that the initial application was not immediately approved, requiring additional data or clarifications.
📋 Key Facts
- The filing pertains to a Type A meeting held with the U.S. Food and Drug Administration (FDA).
- The subject of the NDA is self-administered etripamil nasal spray for treating paroxysmal supraventricular tachycardia.
- The company plans to resubmit its New Drug Application based on FDA feedback.